COVID-19 patients age, comorbidity profiles and clinical presentation related to the SARS-CoV-2 UK-variant spread in the Southeast of France.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
16 09 2021
Historique:
received: 18 03 2021
accepted: 20 07 2021
entrez: 17 9 2021
pubmed: 18 9 2021
medline: 28 9 2021
Statut: epublish

Résumé

The variant 20I/501Y.V1, associated to a higher risk of transmissibility, emerged in Nice city (Southeast of France, French Riviera) during January 2021. The pandemic has resumed late December 2020 in this area. A high incidence rate together with a fast turn-over of the main circulating variants, provided us the opportunity to analyze modifications in clinical profile and outcome traits. We performed an observational study in the University hospital of Nice from December 2020 to February 2021. We analyzed data of sequencing of SARS-CoV-2 from the sewage collector and PCR screening from all positive samples at the hospital. Then, we described the characteristics of all COVID-19 patients admitted in the emergency department (ED) (n = 1247) and those hospitalized in the infectious diseases ward or ICU (n = 232). The UK-variant was absent in this area in December, then increasingly spread in January representing 59% of the PCR screening performed mid-February. The rate of patients over 65 years admitted to the ED decreased from 63 to 50% (p = 0.001). The mean age of hospitalized patients in the infectious diseases ward decreased from 70.7 to 59.2 (p < 0.001) while the proportion of patients without comorbidity increased from 16 to 42% (p = 0.007). Spread of the UK-variant in the Southeast of France affects younger and healthier patients.

Identifiants

pubmed: 34531412
doi: 10.1038/s41598-021-95067-7
pii: 10.1038/s41598-021-95067-7
pmc: PMC8446095
doi:

Substances chimiques

Sewage 0

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

18456

Informations de copyright

© 2021. The Author(s).

Références

Chest. 2021 Feb;159(2):524-536
pubmed: 33069725
Cell. 2021 Jan 7;184(1):64-75.e11
pubmed: 33275900
BMJ Open. 2020 Dec 8;10(12):e045593
pubmed: 33293401
J Clin Med. 2020 Oct 16;9(10):
pubmed: 33081241
Euro Surveill. 2021 Mar;26(9):
pubmed: 33663644
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Science. 2020 Sep 25;369(6511):1603-1607
pubmed: 32732280
Crit Care Med. 2020 Aug;48(8):1196-1202
pubmed: 32697491
Euro Surveill. 2021 Jan;26(1):
pubmed: 33413740
Lancet. 2020 Aug 29;396(10251):603-611
pubmed: 32822564
Nat Med. 2020 Aug;26(8):1205-1211
pubmed: 32546824
BMJ Open. 2021 Jan 11;11(1):e044640
pubmed: 33431495
BMC Infect Dis. 2021 Feb 22;21(1):200
pubmed: 33618678
BMJ. 2021 Mar 9;372:n579
pubmed: 33687922

Auteurs

Johan Courjon (J)

Infectious Diseases Department, Université Côte d'Azur, CHU de Nice, Hôpital Archet 1 Infectiologie 151 route de St Antoine de Ginestière, 06200, Nice, France. courjon.j@chu-nice.fr.
Université Côte d'Azur, Inserm, U1065, C3M, Nice, France. courjon.j@chu-nice.fr.

Julie Contenti (J)

Université Côte d'Azur, Inserm, U1065, C3M, Nice, France.
Emergency Department, Université Côte d'Azur, CHU Nice, Nice, France.

Elisa Demonchy (E)

Infectious Diseases Department, Université Côte d'Azur, CHU de Nice, Hôpital Archet 1 Infectiologie 151 route de St Antoine de Ginestière, 06200, Nice, France.

Jacques Levraut (J)

Emergency Department, Université Côte d'Azur, CHU Nice, Nice, France.

Pascal Barbry (P)

Institut de Pharmacologie Moleculaire et Cellulaire, UMR7275 CNRS/UNS, Valbonne, France.

Géraldine Rios (G)

Institut de Pharmacologie Moleculaire et Cellulaire, UMR7275 CNRS/UNS, Valbonne, France.

Jean Dellamonica (J)

Medical Intensive Care Unit Department, Université Côte d'Azur, CHU Nice, Nice, France.

David Chirio (D)

Infectious Diseases Department, Université Côte d'Azur, CHU de Nice, Hôpital Archet 1 Infectiologie 151 route de St Antoine de Ginestière, 06200, Nice, France.

Caroline Bonnefoy (C)

Virology Department, Université Côte d'Azur, CHU Nice, Nice, France.

Valérie Giordanengo (V)

Université Côte d'Azur, Inserm, U1065, C3M, Nice, France.
Virology Department, Université Côte d'Azur, CHU Nice, Nice, France.

Michel Carles (M)

Infectious Diseases Department, Université Côte d'Azur, CHU de Nice, Hôpital Archet 1 Infectiologie 151 route de St Antoine de Ginestière, 06200, Nice, France.
Université Côte d'Azur, Inserm, U1065, C3M, Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH